Table 2.

IC50 values of 5FU and methotrexate in MDA-MB-435 breast cancer cells transfected with the sense FPGS and with the FPGS-targeted siRNA in comparison with corresponding control cells expressing endogenous FPGS

Folate concentrationIC50 (95% CI)
2.3 μmol/L100 nmol/L20 nmol/L
5FU + LV (μmol/L)
Sense14.14* (12.66, 15.99)12.67 (11.36, 14.30)10.48* (9.29, 11.94)
Control-S6.61 (5.75, 7.54)14.52 (12.59, 17.14)18.94 (16.37, 22.53)
Control-si11.77 (10.51, 13.35)4.84 (4.01, 5.69)7.50 (6.84, 8.22)
siRNA22.85* (19.99, 26.70)5.49 (4.71, 6.31)7.07 (6.56, 7.61)
5FU (μmol/L)
Sense25.73* (22.92, 29.35)7.43 (6.69, 8.25)15.33 (13.65, 17.51)
Control-S12.50 (11.20, 14.12)6.05 (5.26, 6.89)14.30 (12.66, 16.43)
Control-si12.61 (10.78, 15.14)7.08 (6.26, 7.99)5.63 (4.94, 6.35)
siRNA34.66* (27.78, 45.92)8.78 (7.95, 9.72)9.98* (9.00, 11.14)
Methotrexate (nmol/L)
Sense21.52* (19.39, 23.97)11.87* (11.22, 12,57)14.83* (13.91, 15.88)
Control-S28.07 (25.92, 30.63)15.18 (14.47, 15.97)17.60 (16.35, 19.09)
Control-si41.01 (35.22, 49.45)10.75 (10.03, 11.51)16.09 (15.16, 17.13)
siRNA26.63* (24.15, 29.85)7.28* (6.39, 8.14)12.81* (11.98, 13.71)
  • * P < 0.05, compared with corresponding controls.